Menu

PrEP Impact Trial



What is PrEP?

PrEP (HIV Pre-exposure Prophylaxis) is a medicine for HIV negative people that can reduce the risk of acquiring HIV when taken as instructed. Pre-exposure means it is taken before sex (i.e. before any potential exposure to HIV), and Prophylaxis means "a treatment given to prevent infection" – in this case HIV.


What is PrEP made of?

PrEP is made up of two drugs, Tenofovir and Emtricitabine, which are known as antiretroviral medicines and have been used as part of HIV treatment for many years. You may know them by the brand name, Truvada. However, there are generic forms of the drug with the same active ingredients.


​Who would benefit from PrEP?

You could benefit from PrEP if you are considered to be at high risk of HIV. PrEP can be used as a way to reduce your risk of HIV if you are HIV negative and don’t always use condoms.

PrEP is not a vaccine and only provides protection from HIV so long as you continue to take it as prescribed. It is important to remember that PrEP will not protect you from acquiring other STIs. This is an important advantage of using condoms.


What is the PrEP Impact Trial?

The PrEP Impact Trial aims to answer key questions about the use of PrEP in England under real world conditions and at sufficient scale. The results of the trial will inform service commissioners (funders) on how to deliver a PrEP programme in the future, when PrEP will be made available as part of routine care in sexual health services.

Major questions that the trial aims to address are:

  • What proportion of people attending sexual health clinics will be at high risk and eligible for PrEP?
  • What proportion of people who are offered PrEP will accept it?
  • What is the length of PrEP use in those who accept the offer?
  • What is the impact on HIV incidence in the population?
  • What is the impact on STI incidence in the population?

The trial started enrolling participants in October 2017 and is plans to continue recruiting new participants to mid July 2020 to a total of up to 26,000 participants.

The trial is conducted in sexual health clinics across England. All specialised genitourinary medicine (GUM) clinics (i.e. level 3 sexual health clinics) have been invited to participate in the trial.

Visit thePrEP Impact Trial website for more information.


How do I join the PrEP Impact Trial?

The PrEP Impact Trial is recruiting participants from across England that fall into one of two groups:

  • MSM (men who have sex with men)
  • Women and other groups

Cornwall and the Isles of Scilly has currently reached capacity for MSM participants, but is still recruiting for women and other groups.

Find out more about joining the PrEP trial


Are you a PrEP Impact Trial participant?

If you are currently enrolled on the PrEP Impact Trial in Cornwall and the Isles of Scilly, your point of contact for clinic visits and enquiries is Jess.

You can contact Jess by emailing jessica.wise@brook.org.uk or by calling the main phone line on 0300 303 0714.